AKUS Akouos, Inc.

Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing loss. Leveraging its precision genetic medicine platform that incorporates a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. The Company’s lead product candidate, AK-OTOF, is a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene.

$13.85  -0.21 (-1.49%)
As of 04/09/2021 15:59:55 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/26/2020
Outstanding shares:  34,402,023
Average volume:  258,981
Market cap:   $477,156,059
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    00973J101
ISIN:        US00973J1016
Sedol:      BKPVFN5
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   1.54
PS ratio:   0.00
Return on equity:   -11.62%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy